DanCann Pharma A/S informs about the outcome of the TO1
COPENHAGEN, Denmark, 21 September 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby today informs, that the period for exercising warrants of series TO1 for subscription of shares in DanCann Pharma ended Friday (17 September 2021). In total, 0 TO1 was used for subscription, implying a utilization rate of 0 percent. The subscription price was DKK 6.00 / share, which exceeded the share price, which as of Friday's closing price was DKK 3.855 / share. CEO of DanCann Pharma, Jeppe Krog Rasmussen, comments:- As expected, the outcome of the warrants was in line